CD4 and depressive symptom measurement: However, these findings should not be interpreted as lack of DAA efficacy in these groups as SVR12 rates were still high in patients with CD4 <200 cells/mm3 (88.8% [n = 27]), depression (90.5% [n = 148]), and substance abuse (89.8% [n = 157]).